Providence Medical Technology Inc. announced it received FDA 510(k) clearance for the DTRAX spinal system, intended to be used in posterior cervical fusion in patients with cervical degenerative disease, according to a company press release.

“With the FDA 510(k) clearance of DTRAX spinal system, Providence now has the only sterile-packaged, single-use set of instruments specifically cleared for posterior cervical fusion,” Jeff Smith, Providence CEO, said in the release. “Our unique, single-use instruments assist surgeons in performing the steps of a traditional posterior cervical fusion. We believe DTRAX represents a landmark innovation for cervical fusion benefiting patients, surgeons, facilities and payers.”